Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody: mongersen sodium | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 3,139 | 0.85 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 8041
Sealed predictions
- SMAD7 in dopamine neurons, braak-0.36 (p 0.347) → -0.42 (p 0.266)receipt 8048
Swarm cases
receipt 8048: SMAD7 in dopamine neurons, braak
- power
- full sample -0.36 (p 0.137, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.41 (p 0.089, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.046, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.28, sign flips 0; without severely affected donors -0.36 (p 0.137, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.69 (p 0.0016, n 18) vs -0.36 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SMAD7 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SMAD7 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.40 p 0.155 (needs p < 2.6e-4)
Receipts
loading the receipts